Furthermore, the great advantage of PROTACs, and of those that recruit MDM2, lies in the possibility of degrading previously “undruggable proteins”, that is, they allow for the degradation of targets which do not have an active site, thus being able, with these new molecules, to interfere with new signaling pathways crucial for the development and proliferation of cancer cells, something that has never been explored before [9]. This evidence concerns the gene MDM2 and cancer.